JAZZ - Jazz Pharmaceuticals Non-GAAP EPS of -$0.07 misses by $1.19 revenue of $972.12M misses by $3.75M guidance in-line
- Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q4 Non-GAAP EPS of -$0.07 misses by $1.19 .
- Revenue of $972.12M (+8.4% Y/Y) misses by $3.75M .
- 2023 total revenue guidance of $3,675 to $3,875 million, 3% growth at the mid-point, vs. consensus of $3.76B.
For further details see:
Jazz Pharmaceuticals Non-GAAP EPS of -$0.07 misses by $1.19, revenue of $972.12M misses by $3.75M, guidance in-line